AAAAAA

   
Results: 1-20 |
Results: 20
HEALTH-RELATED QUALITY-OF-LIFE AND SEQUELAE IN PATIENTS TREATED WITH BRACHYTHERAPY AND EXTERNAL-BEAM IRRADIATION FOR LOCALIZED PROSTATE-CANCER
Authors: JOLY F BRUNE D COUETTE JE LESAUNIER F HERON JF PENY J HENRYAMAR M
Citation: F. Joly et al., HEALTH-RELATED QUALITY-OF-LIFE AND SEQUELAE IN PATIENTS TREATED WITH BRACHYTHERAPY AND EXTERNAL-BEAM IRRADIATION FOR LOCALIZED PROSTATE-CANCER, Annals of oncology, 9(7), 1998, pp. 751-757
CONTROL OF DELAYED NAUSEA AND VOMITING WITH GRANISETRON PLUS DEXAMETHASONE OR DEXAMETHASONE ALONE IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY - A DOUBLE-BLIND, PLACEBO-CONTROLLED, COMPARATIVE-STUDY
Authors: GOEDHALS L HERON JF KLEISBAUER JP PAGANI O SESSA C GIGER K CAVALLI F LUDWIG C AAPRO M BLEIBERG H DEWASH G DICATO M TAGNON A VANSTRAELEN D VINDEVOGHEL A ABRATT R FALKSON G BARLEY V CARMICHAEL J COLEMAN R DAVIDSON N GRIEVE R HARPER P ROBERTS J RUSTIN G NAMAN H SCHNEIDER M NOBLE A NETTER P CUPISSOL D BALMES P CALS L KHAYAT D CATIMEL G DUTIN JP BOUFETTE P ADENIS L MISSET J COLLERY P NOUVET G CHAVAILLON JM BLANCHON F POIRIER R ARNAUD A LECAER H CARLES P MUIR J BONNAUD F MARQUESTE L CLAVIER J GUERIN J TAYTARD A KEIZER H NORTIER J SLEE P WILS J RODENBURG C BURGHOUTS J DEWIT R GARCIAGIRON C JIMENEZLACAVE A CRUZHERNANDEZ J MASSUTISUREDA B HANS K FUCHS R KRIEGMAIR M SCHULLER J LAHOUSEN M PANNUTI F MONFARDINI S NILSSON S
Citation: L. Goedhals et al., CONTROL OF DELAYED NAUSEA AND VOMITING WITH GRANISETRON PLUS DEXAMETHASONE OR DEXAMETHASONE ALONE IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY - A DOUBLE-BLIND, PLACEBO-CONTROLLED, COMPARATIVE-STUDY, Annals of oncology, 9(6), 1998, pp. 661-666
CISPLATIN CARBOPLATIN/CYCLOPHOSPHAMIDE (CCP) VS CISPLATIN/CYCLOPHOSPHAMIDE (CP) IN STAGE III-IV EPITHELIAL OVARIAN-CANCER - A FRENCH RANDOMIZED PHASE-III STUDY/
Authors: HERON JF JOLY F KERBRAT P CHAUVERGNE J MAYER F WEBER B CHINETCHARROT P CROUET H GOUPIL A LESECH JM LEBRUNJEZEKOVA D NAMER M MARTIN C GUASTALLA JP LHOMME C
Citation: Jf. Heron et al., CISPLATIN CARBOPLATIN/CYCLOPHOSPHAMIDE (CCP) VS CISPLATIN/CYCLOPHOSPHAMIDE (CP) IN STAGE III-IV EPITHELIAL OVARIAN-CANCER - A FRENCH RANDOMIZED PHASE-III STUDY/, Annals of oncology, 9, 1998, pp. 315-315
HEALTH-RELATED QUALITY-OF-LIFE AND SEQUELAE IN PATIENTS TREATED WITH EXTERNAL-BEAM IRRADIATION (EBI) AND BRACHYTHERAPY FOR LOCALIZED PROSTATE-CANCER (LPC)
Authors: JOLY F BRUNE D COUETTE JE HERON JF HENRYAMAR M
Citation: F. Joly et al., HEALTH-RELATED QUALITY-OF-LIFE AND SEQUELAE IN PATIENTS TREATED WITH EXTERNAL-BEAM IRRADIATION (EBI) AND BRACHYTHERAPY FOR LOCALIZED PROSTATE-CANCER (LPC), European journal of cancer, 33, 1997, pp. 137-137
TOPOTECAN VERSUS PACLITAXEL FOR THE TREATMENT OF RECURRENT EPITHELIALOVARIAN-CANCER
Authors: HUININK WTB GORE M CARMICHAEL J GORDON A MALFETANO J HUDSON I BROOM C SCARABELLI C DAVIDSON N SPANCZYNSKI M BOLIS G MALMSTROM H COLEMAN R FIELDS SC HERON JF
Citation: Wtb. Huinink et al., TOPOTECAN VERSUS PACLITAXEL FOR THE TREATMENT OF RECURRENT EPITHELIALOVARIAN-CANCER, Journal of clinical oncology, 15(6), 1997, pp. 2183-2193
CARBOPLATIN PLUS PACLITAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN-CANCER - PRELIMINARY-RESULTS OF A PHASE-I STUDY
Authors: LHOMME C KERBRAT P LEJEUNE C GUASTALLA JP FUMOLEAU P GOUPIL A HERON JF CASSIN MA PRUVOT I SOARES JA CHAZARD M
Citation: C. Lhomme et al., CARBOPLATIN PLUS PACLITAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN-CANCER - PRELIMINARY-RESULTS OF A PHASE-I STUDY, Seminars in oncology, 23(5), 1996, pp. 48-54
HIGH-DOSE CHEMOTHERAPY IN ADVANCED OVARIAN-CARCINOMA WITH BULKY RESIDUAL DISEASE
Authors: HERON JF LHOMME C KERBRAT P MAYER F CHEVALLIER B GOUPIL A VENNIN P LEBRUN D CHAUVERGNE J AYME Y NAMER M
Citation: Jf. Heron et al., HIGH-DOSE CHEMOTHERAPY IN ADVANCED OVARIAN-CARCINOMA WITH BULKY RESIDUAL DISEASE, European journal of cancer, 31A, 1995, pp. 503-503
A PHASE-II STUDY OF TAXOL(R) (T) (PACLITAXEL) OVER 3 HOURS (H) IN 192PLATINUM PRETREATED PATIENTS (PTS) FOR OVARIAN-CARCINOMA (OC)
Authors: LHOMME C GUASTALLA JP DAUPLAT J FERRERO JM OBERLING F VENNIN P POUILLART P FUMOLEAU P KERBRAT P TUBIANA N HERON JF BUGAT R BACHELOT T SCHREINEROVA M FLEURY J NAMER M DUFOUR P DIERAS V SOLARMICHEL P PRUVOT I CHANEZ MA GARET F CHAZARD M PELLAECOSSET B
Citation: C. Lhomme et al., A PHASE-II STUDY OF TAXOL(R) (T) (PACLITAXEL) OVER 3 HOURS (H) IN 192PLATINUM PRETREATED PATIENTS (PTS) FOR OVARIAN-CARCINOMA (OC), European journal of cancer, 31A, 1995, pp. 507-507
COST EVALUATION OF 2 CHEMOTHERAPIES IN OVARIAN-TUMORS BASED ON A CONTROLLED CLINICAL-TRIAL (CCT)
Authors: MACELESECH J JOLY F DROULERS C HERON JF
Citation: J. Macelesech et al., COST EVALUATION OF 2 CHEMOTHERAPIES IN OVARIAN-TUMORS BASED ON A CONTROLLED CLINICAL-TRIAL (CCT), European journal of cancer, 31A, 1995, pp. 508-508
NEOADJUVANT MVAC CHEMOTHERAPY IN BLADDER-CANCER - THE CENTER-FRANCOIS-BACLESSE (CFB) EXPERIENCE
Authors: JOLY F HERON JF MACELESSECH J DERANIERI J BRUNE D PENY J COUETTE JE
Citation: F. Joly et al., NEOADJUVANT MVAC CHEMOTHERAPY IN BLADDER-CANCER - THE CENTER-FRANCOIS-BACLESSE (CFB) EXPERIENCE, European journal of cancer, 31A, 1995, pp. 1151-1151
IS NAVOBAN(R) (TROPISETRON) AS EFFECTIVE AS ZOFRAN(R) (ONDANSETRON) IN CISPLATIN-INDUCED EMESIS
Authors: MARTY M KLEISBAUER JP FOURNEL P VERGNENEGRE A CARLES P LORIAKANZA Y SIMONETTA C DEBRUIJN KM LAURAINE P DIDIER A CUPISSOL D BERGERAT JP PUJAZON MC HERON JF DRENO B TAYTARD A GUERIN JC CLAVIER J ROBINET G BLANCHON F BALMES P MUIR JF PAILLOTIN D POIRIER R BONNETERRE J MELLONI B ROCHE H DEPIERRE A PLAGNE R SOUQUET PJ ARMAND JP DEFORNI M
Citation: M. Marty et al., IS NAVOBAN(R) (TROPISETRON) AS EFFECTIVE AS ZOFRAN(R) (ONDANSETRON) IN CISPLATIN-INDUCED EMESIS, Anti-cancer drugs, 6, 1995, pp. 15-21
SINGLE-AGENT ORAL GRANISETRON FOR THE PREVENTION OF ACUTE CISPLATIN-INDUCED EMESIS - A DOUBLE-BLIND, RANDOMIZED COMPARISON WITH GRANISETRONPLUS DEXAMETHASONE AND HIGH-DOSE METOCLOPRAMIDE PLUS DEXAMETHASONE
Authors: HERON JF
Citation: Jf. Heron, SINGLE-AGENT ORAL GRANISETRON FOR THE PREVENTION OF ACUTE CISPLATIN-INDUCED EMESIS - A DOUBLE-BLIND, RANDOMIZED COMPARISON WITH GRANISETRONPLUS DEXAMETHASONE AND HIGH-DOSE METOCLOPRAMIDE PLUS DEXAMETHASONE, Seminars in oncology, 22(4), 1995, pp. 24-30
METHODOLOGY OF THE DEVELOPMENT OF THE DIA GNOSTIC AND THERAPEUTIC STANDARDS, OPTIONS AND GUIDELINES IN ONCOLOGY
Authors: FERVERS B BONICHON F DEMARD F HERON JF MATHOULIN S PHILIP T RENAUDSALIS JL BEY P
Citation: B. Fervers et al., METHODOLOGY OF THE DEVELOPMENT OF THE DIA GNOSTIC AND THERAPEUTIC STANDARDS, OPTIONS AND GUIDELINES IN ONCOLOGY, Bulletin du cancer, 82(10), 1995, pp. 761-767
STANDARDS, OPTIONS AND GUIDELINES FOR APP LICATIONS IN CHEMOTHERAPY
Authors: HERON JF FERVERS B LATOUR JF SOMMELET D CHAUVERGNE J PHILIP T
Citation: Jf. Heron et al., STANDARDS, OPTIONS AND GUIDELINES FOR APP LICATIONS IN CHEMOTHERAPY, Bulletin du cancer, 82(10), 1995, pp. 823-834
ORAL GRANISETRON ALONE AND IN COMBINATION WITH DEXAMETHASONE - A DOUBLE-BLIND RANDOMIZED COMPARISON AGAINST HIGH-DOSE METOCLOPRAMIDE PLUS DEXAMETHASONE IN PREVENTION OF CISPLATIN-INDUCED EMESIS
Authors: HERON JF GOEDHALS L JORDAAN JP CUNNINGHAM J CEDAR E
Citation: Jf. Heron et al., ORAL GRANISETRON ALONE AND IN COMBINATION WITH DEXAMETHASONE - A DOUBLE-BLIND RANDOMIZED COMPARISON AGAINST HIGH-DOSE METOCLOPRAMIDE PLUS DEXAMETHASONE IN PREVENTION OF CISPLATIN-INDUCED EMESIS, Annals of oncology, 5(7), 1994, pp. 579-584
PHASE-II TRIAL OF INTRAPERITONEAL CARBOPLATIN IN OVARIAN-CARCINOMA PATIENTS WITH MACROSCOPIC RESIDUAL DISEASE AT 2ND-LOOK LAPAROTOMY
Authors: GUASTALLA JP LHOMME C KERBRAT P MAYER F NAMER M GOUPIL P CHARROT P HERON JF CHAZARD M RICHARD I CHAUVIN F
Citation: Jp. Guastalla et al., PHASE-II TRIAL OF INTRAPERITONEAL CARBOPLATIN IN OVARIAN-CARCINOMA PATIENTS WITH MACROSCOPIC RESIDUAL DISEASE AT 2ND-LOOK LAPAROTOMY, Annals of oncology, 5(2), 1994, pp. 127-132
BREAST-CANCER IN MALE AND MUTATION OF AND ROGENS RECEPTOR
Authors: LOBACCARO JM LUMBROSO S POUJOL N BELON C NAMER M PUJOL H CUTULI BF SOBOL H HANS D LESIMPLE T AYME Y LENOIR G HERON JF STOPPALYONNET D BIGNON Y SULTAN C
Citation: Jm. Lobaccaro et al., BREAST-CANCER IN MALE AND MUTATION OF AND ROGENS RECEPTOR, Pathologie et biologie, 42(10), 1994, pp. 1053-1054
MALE BREAST-CANCER AND THE ANDROGEN RECEPTOR GENE
Authors: LOBACCARO JM LUMBROSO S BELON C GALTIERDEREURE F BRINGER J LESIMPLE T HERON JF PUJOL H SULTAN C
Citation: Jm. Lobaccaro et al., MALE BREAST-CANCER AND THE ANDROGEN RECEPTOR GENE, Nature genetics, 5(2), 1993, pp. 109-110
OVARIAN TUMOR WITH HEPATOID DIFFERENTIATION - REPORT OF ONE CASE AND REVIEW OF THE LITERATURE
Authors: BADREDDINE J RABOUILLE Y HERON JF MANDARD AM
Citation: J. Badreddine et al., OVARIAN TUMOR WITH HEPATOID DIFFERENTIATION - REPORT OF ONE CASE AND REVIEW OF THE LITERATURE, Annales de pathologie, 13(1), 1993, pp. 37-39
NEOADJUVANT CHEMOTHERAPY FOR STAGES IIB-I II CERVICAL CANCERS - LONG-TERM FOLLOW-UP OF PLURICENTRIC RANDOMIZED STUDY OF 151 PATIENTS
Authors: CHAUVERGNE J LHOMME C ROHART J HERON JF AYME Y GOUPIL A FARGEOT P DAVID M
Citation: J. Chauvergne et al., NEOADJUVANT CHEMOTHERAPY FOR STAGES IIB-I II CERVICAL CANCERS - LONG-TERM FOLLOW-UP OF PLURICENTRIC RANDOMIZED STUDY OF 151 PATIENTS, Bulletin du cancer, 80(12), 1993, pp. 1069-1079
Risultati: 1-20 |